...
首页> 外文期刊>Molecular simulation >Terpenoids as promising therapeutic molecules against Alzheimer's disease: amyloid beta- and acetylcholinesterase-directed pharmacokinetic and molecular docking analyses
【24h】

Terpenoids as promising therapeutic molecules against Alzheimer's disease: amyloid beta- and acetylcholinesterase-directed pharmacokinetic and molecular docking analyses

机译:Terpenoids作为对阿尔茨海默病的有前途的治疗分子:淀粉样蛋白β-和乙酰胆碱酯酶 - 定向的药代动力学和分子对接分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Alzheimer's disease (AD) is a progressive neurological disorder of brain encompassing deterioration of cognitive functions and behavioural changes eventually leading to cell death and dementia. Several attempts have been made to treat AD by the use of combined drug therapy against acetylcholinesterase (AChE) and amyloid beta (A) simultaneously with the aim to delay its progress. However, side effects of long-term administration of these drugs have directed research towards development of a new generation of therapeutics based on natural compounds. In this regard, one hundred terpenoids were analysed for their inhibitory potential against AChE and A through molecular docking approach. The selected terpenoids were further screened for their pharmacokinetic properties, among which only 25 terpenoids were found to fulfil all the ADMET descriptors and drug likeness properties which are essential for ensuring the development of safer drugs. A triterpene, nimbolide, was found to be the most potent and safe inhibitor for both AChE and A as compared to their respective drugs/known inhibitors. The results of docking were further confirmed using molecular dynamics simulation analysis of complexes of nimbolide with both the targets. Thus, the present work makes a foundation for further clinical investigations of nimbolide as a drug against AD.
机译:阿尔茨海默病(AD)是一种脑卒中的脑卒中的脑疾病,包括认知功能恶化,最终导致细胞死亡和痴呆的行为变化。已经通过使用与乙酰胆碱酯酶(ACHE)和淀粉样蛋白β(A)同时使用组合的药物治疗来治疗AD的几次尝试,以延迟其进展。然而,长期施用这些药物的副作用对基于天然化合物的新一代治疗剂进行了研究。在这方面,分析了一百三萜件,以通过分子对接方法对疼痛和A的抑制潜力进行分析。进一步筛选所选的三萜类化物质性质,其中仅发现25萜类化合物来满足所有呼吸描述符和药物象征性,这对于确保更安全的药物的发展至关重要。发现三个腹蛋白是疼痛和A与其各自的药物/已知抑制剂相比的最有效和安全的抑制剂。利用弯曲粘合剂与靶标的分子动力学模拟分析进一步证实了对接的结果。因此,目前的作品为尼米骨苷的进一步临床研究是针对广告的药物的进一步临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号